CARDIAC BIOMARKERS MARKET ANALYSIS

Market Concentration and Competitive Landscape

Close-monitor your Competitor's Move, Request sample copy

Rising Focus on Innovation and Development of Novel Biomarkers

The growing focus of leading industry players and research institutions on innovation and development of novel cardiac biomarkers is another major factor fueling the growth of this market. Currently available biomarker tests only facilitate the detection of myocardial necrosis and injury. However, clinicians also require biomarkers that can provide accurate information on other aspects such as myocardial stress, ischemia, remodeling, and other pre-damage states. Therefore, newer biomarkers are being pursued that can enable the detection of cardiac abnormalities at early pre-damage stages as well. Considerable investments are being made for identifying novel biomarkers through omics-based techniques like proteomics and metabolomics. Some of the promising novel cardiac biomarkers in clinical trials or early stages of development include soluble ST2, galectin-3, matrix metalloproteinases, placental growth factor, ischemia-modified albumin, and others. The development of panels of multiple biomarkers is also gaining attention for facilitating comprehensive cardiac risk assessment. The pipeline of innovative biomarkers in the clinical development and approval phases will continue fueling market revenue in the coming years.